A woman with dark hair wearing a striped jacket, smiling at the camera.

Anupam R. Verma, MD

Languages spoken: English, Hindi, Gujarati

Academic Information

Departments Adjunct - Pediatrics

Divisions: Hematology/Oncology

Board Certification

  • American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
  • Indian Board of Pediatrics
  • American Board of Pediatrics (Pediatrics)

Anupam Verma, MD, is an assistant professor and physician in the Division of Pediatric Hematology and Oncology at the University of Utah, an investigator at the Huntsman Cancer Institute (HCI), and a member of the Experimental Therapeutics program. In her clinical work at Primary Children's Medical Center, she cares for children with blood diseases and cancers.

As a researcher, Verma is involved in developing and conducting early phase clinical trials for children with leukemia and lymphomas. At HCI, her research focus is novel target drug development to advance cures for pediatric cancer.

Verma is board-certified in pediatrics and recently completed a fellowship in pediatric hematology and oncology at the University of Utah and Primary Children's Medical Center. She has been an assistant professor of pediatrics at the University of Utah School of Medicine since 2009. Verma completed her pediatric residency at Brookdale University Hospital and Medical Center in Brooklyn, New York. She worked as a senior resident doctor in pediatrics at All India Institute of Medical Sciences in New Delhi, India. She received her medical degree and her doctorate in pediatrics from Baroda Medical College, India.

Education History

Professional Medical University of Baroda Medical College
 MBBS
Residency University of Baroda Medical College
 Resident
Chief Resident All India Institute of Medical Sciences
 Senior Registrar
Residency Brookdale University Hospital Medical Center
 Resident
Chief Resident Brookdale University Hospital Medical Center
 Chief Resident
Fellowship University of Utah
 Fellow

Selected Publications

Journal Article

  1. Marisol Betensky, MDMPH, Anh Thy Nguyen, MSPH, Cristina Tarango, MD, Anupam R Verma, MD, Rukhmi Bhat, MDMS, Nicole Kucine, MD, Charles Nakar, MD, Gary Woods, MD, Frances L Hamblin, MSHS, RN, Ernest Amankwah, PhD, Neil A Goldenberg, MD PhD (2019). Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial. Blood, 134(Supplement_1), 636.
  2. Nagelhout E, Sudtin T, Grahmann B, Wilson A, Scott B, Gardner E, Spraker-Perlman H, Verma A, Fluchel MN, Wu Y (2018). Social media use among parents and caregivers of a child with cancer. Journal of pediatric oncology nursing,
  3. Davis KL, Agarwal AM, Verma A (2017). Checkpoint inhibition in pediatric hematologic malignancies. Pediatric hematology and oncology, 34(6-7), 379-394.
  4. Anupam Verma, Karin Chen, Cynthia Bender, Nathan Gorney, Whitney Leonard, Phillip Barnett (2019). PEGylated E. Coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi Availability. Pediatric hematology and oncology, 36(5), 277-286.
  5. John Goldberg, Julia Bender, Sima Jeha, Maria Luisa Sulis, Rebecca Gardner, Jessica Pollard, Victor Aquino, Theodore Laetsch, Naomi Winick, Cecilia Fu, Leigh Marcus, Weili Sun, Anupam Verma, Michael Burke, Phoenix Ho, Thomas Manley, Rajen Mody, Wendy Tcheng, Blythe Thomson, Julie Park, Richard Sposto, Yoav Messinger, Nobuko Hijiya, Paul Gaynon & Julio Barred (2020). A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatric hematology and oncology, 37(6), 465-474.
  6. Batchelor L , Sweeney N , Davis A , Trakhimets O , Verma A , Borga C , Te Kronnie G , Trede Ns , Miles R , Frazer J (2012). Zebrafish: a novel approach to understanding lymphomagenesis and treatment responses. British journal of haematology,
  7. Soldi R, Horrigan SK, Cholofy MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma (2015). Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime ß-Catenin Pathway Inhibitors. Journal of medicinal chemistry,
  8. Heilmann A, Schrock A, He J, Nahas M, Curran K, Shukla N, Cramer S, Draper L*, Verma A, Erlich R, Ross J, Stephens P, Miller V, Ali S, Verglio J, Tallman M, Mughal (2017). Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia. Leukemia,
  9. Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne A, Whitlock, J (2018). Outcome of children with refractory or mutiply relapsed B precursor acute lymphoblastic leukemia: a TACL study. Leukemia,
  10. Franco Locatelli, James A. Whitlock, Christina Peters, Christiane Chen-Santel, Victoria Chia, Robyn M. Dennis, Kenneth M. Heym, Aaron J. Katz, Michael A. Kelsh, Richard Sposto, Huakang Tu, Catherine A. Tuglus, Anupam Verma, Luciana Vinti, Jennifer J. Wilkes, Nathalya Zubarovskaja, Gerhard Zugmaier, Arend von Stackelberg, Weili Su (2020). Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia,
  11. Luke Maese, DO, Tawny Saleh, MD, Roberto E. Montenegro, MD, Anupam Verma, MD, Jill M. Stein, MD, Lance K. Erickson, PA(ACSP), Christopher T. Sower,MD, Karl Herman, MD, Michelle Kinsey, MD, John M. Opitz, MD, Kenneth M. Boucher, PhD, Marvin Nelson,MD, Hung C. Tran, MD, John D. MacKenzie, MD, Steven G. DuBois, MD, David Dansie, Joshua D. Schiffman, M Association of Cervical Rib Anomalies in Pediatric Malignancy. Pediatrics,
  12. Michael J Burke, Rumen Kostadinov, Richard Sposto, Lia Gore, Shannon M Kelley, Cara Rabik, Jane B. Trepel, Min-Jung Lee, Akira Yuno, Sunmin Lee, Deepa Bhojwani, Sima Jeha, Bill H Chang, Maria Luisa Sulis, Michelle L. Hermiston, Paul Gaynon, Van Huynh, Anupam Verma, Rebecca Gardner, Kenneth M. Heym, Robyn M Dennis, David S Ziegler, Theodore W. Laetsch, Javier E Oesterheld, Steven G Dubois, Jessica A Pollard, Julia Glade-Bender, Todd M Cooper, Joel A Kaplan, Midhat S Farooqi, Byunggil Yoo, Erin Guest, Alan S Wayne and Patrick A Brow (2020). Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clinical cancer research, 26, 2297¿2307.
  13. John P. Mulcaire-Jones , David K. Bailly, Deborah U. Frank, Anupam R. Verma, Bradley J. Barney, Heather M. Siefke (2020). Spontaneous aortic thrombosis in neonates: a case report and review of literature. Cardiology in the young, 30, 95-99.
  14. Verma A, Zhou H, Chin S, Bruggers C, Kestle J, Khatua (2011). EGFR as a predictor of relapse in myxopapillary ependymoma. Pediatric blood & cancer,
  15. Mangum DS*, Verma A, Weng C, Sheng X, Larsen R, Kirchhoff AC, Druzgal C, Fluchel M (2015). A comparison of central lines in pediatric oncology patients: Early removal and patient centered outcomes. Pediatric blood & cancer, 60(11), 1890-5.
  16. Christopher A. Ours, Fiorella Iglesias-Cárdenas, Erin Morales Ubico, Archana M Agarwal, Reha M. Toydemir, Anupam Verm Challenges in the Diagnosis of Myeloid Leukemia of Down Syndrome: Experience from a Single Institution. Pediatric blood & cancer,
  17. Everitt MD, Verma AR, Saarel E (2011). The wearable external cardiac defibrillator for cancer patients at risk for sudden cardiac death. Community oncology, 8(9), 400-403.
  18. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss D (2011). Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS medicinal chemistry letters, 2(12), 901-912.
  19. Gupta S*, Doyle K, Mosbruger T, Butterfield A, Weston A, Ast A*, Kaadige M, Sharma S, Verma (2017). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924.
  20. Verma AR, OP Shukl (2004). Usher's Syndrome. 56, 119-121.

Review

  1. Glade Bender J, Verma A, Schiffman JD (2015). Translating genomic discoveries to the clinic in pediatric oncology. Current opinion in pediatrics,
  2. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma (2011). Targeting Axl and Mer Kinases in Cancer. Molecular cancer therapeutics, (Oct 2011), 1763-73.
  3. Verma A, Maese L, Carter-Febres M, Bender Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. 2011:11, 1-16.

Letter

  1. Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare (2018). A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica, 103(2), e87-e91.
  2. Mollard A, Warner SL, Call L, Wade M, Bearss J, Verma AR, Sharma S, Bearss DJ, Vankayalapati (2011). Homology structure-based design, synthesis and biological evaluation of a series of novel Axl and Mer kinase Inhibitors. ACS medicinal chemistry letters, 12(2), 907-912.

Abstract

  1. Verma A, Linder L, Knackstedt E, Gerdy C, Abouzelof R, Lemons R (12/7/2105). Reduction in Inpatient Central Line Associated Blood Stream Infection Post Implementation of Bundled Care Measures in Patients with Benign and Malignant Hematological Conditions in a Single Pediatric Institution [Abstract]. Blood.
  2. Verma A, Halford Z, Corsi M*, Beckstrom D* (12/3/2015). Retrospective Analysis of Clinical Response in Children with Severe Immune Thrombocytopenia Undergoing Treatment with Intravenous Immune Globulin [Abstract]. Blood, 126(23), 4652.
  3. Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis RM, Heym KM, Eckroth E, Vandergiesse J, Gaynon PS, Wayne AS, Whitlock JA (12/7/2015). Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium [Abstract]. Blood.
  4. Verma AR, Fluchel M, Barnette P (Oct 18-20, 2011). Familial Hemophagocytic Lymphohistiocytosis presenting with Nonimmune Hydrops Fetalis [Abstract]. Blood, 56(4), 701.
  5. Verma AR, Rodgers G, Yaish H (Dec 3-7, 2010). Type 3 Von Willebrand Disease with Alloantibodies and Its Challenging Management During Episode of Bleeding [Abstract]. Blood.
  6. Verma A, Frazer JK, Trakhimets A, Heaton W, Bearrs J, Warner S, Bearrs D, Sharma S (Dec 2011). A Novel Dual AXL/Mertk and Aurora Kinase Inhibiton Active Against T Cell Acute Lymphoblastic Leukemia [Abstract]. Blood, 118, 1519.
  7. Michael J. Burke, Patrick Brown, Lia Gore, Richard Sposto, Deepa Bhojwani, Bill H Chang, Steven G. Dubois, Paul S Gaynon, Julia Glade-Bender, Kenneth Matthew Heym, Maria Luisa Sulis, Jessica A. Pollard, Anupam Verma, and Van Huynh. (12/6/2014). Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium [Abstract]. Blood, 124(21), 3650.
  8. Burke MJ, Brown P, Sposto R, Gore L, Verma A, Wayne AS (12/4/2016). Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium [Abstract]. Blood.
  9. Schrock A, Heilmann A, He J, Nahas M, Curran K, Shukla N, Murphy S, Ganesan S, Cramer S, Draper L, Verma A, Phillips C, Kuebitz S, Ross J, Stephens P, Miller VA, Ali S, Verglio J, Tallman MS, Mughal TL (12/4/2016). Clinical Utility of Comprehensive Genomic Profiling to Detect Novel, Previously Unidentified Fusions in Patients with Acute Lymphoblastic Leukemia [Abstract]. Blood.
  10. Verma AR, Mangum DS*, Druzgal C, Owen C, Collingridge D, Fluchel (2010). Subcutaneous Ports Versus External Venous Catheters from the Perspective of Pediatric Oncology Patients and their Families.
  11. Mangum DS*, Verma AR, Druzgal C, Larsen R, Fluchel (2010). External Venous Catheters Have a Higher Rate of Early Removal than Subcutaneous Ports in Pediatric Cancer Patients.
  12. Verma A, Zhou H, Chin S, Bruggers C, Kestle J, Khatua (2010). EGFR as a predictor of relapse and a potential therapeutic target in recurrent disseminated myxopapillary ependymoma.
  13. Ast A*, Putnam A, Schiffman J, Hill A, Prlman E, South S, Paxton C, Verma (2015). DICER1 showing its ugly face again. A novel DICER1 mutation identified in a female with an undifferentiated renal sarcoma with cystic nephroma background.
  14. Meznarich JM*, Verma (2016). Cytomegalovirus retinitis diagnosed by vitreous aspiration in a patient with T-cell acute lymphoblastic Leukemia.
  15. Iglesias F*, Ours C*, Verma (2017). Novel variant of the serpinc1 gene in antithrombin deficiency.
  16. Elaine M Fan, Reha M Toydemir, Phillip E Barnette, and Anupam Verm (2021). Case Series of Children Presenting with Chronic Myeloid Leukemia in Blast Phase- A Single Institute Experience.
  17. Maria Carter Febres, Zachary Kastenberg, Mouied Alashari, Christopher Roach, Anupam Verm (2021). Teratoid Wilms Tumor Presenting as Bilateral Renal Tumor and Recurrence as Triphasic Wilms – a Case Report.